CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea

Jae-Lyun Lee, Jeong Eun Kim, Jin-Hee Ahn, Dae-Ho Lee, Jungshin Lee, Choung-Soo Kim, Jun Hyuk Hong, Bumsik Hong, Cheryn Song, Hanjong Ahn

Cancer Research and Treatment. 2010;42(1):12-17. Published online 2010 March 31 DOI: https://doi.org/10.4143/crt.2010.42.1.12

Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea

Jae-Lyun Lee, Jeong Eun Kim, Jin-Hee Ahn, Dae-Ho Lee, Jungshin Lee, Choung-Soo Kim, Jun Hyuk Hong, Bumsik Hong, Cheryn Song, Hanjong Ahn

Cancer Research and Treatment. 2010;42(1):12

Link1

Link2

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

Robert W. Ross, Tomasz M. Beer, Susanna Jacobus, Glenn J. Bubley, Mary-Ellen Taplin, Christopher W. Ryan, Jiaoti Huang, William K. Oh,

Cancer. 2008;112(3):521-526

Link1 Link2

Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer

J-C Eymard, F. Priou, A. Zannetti, A. Ravaud, D. Lepillé, P. Kerbrat, P. Gomez, B. Paule, D. Genet, P. Hérait, E. Ecstein-Fraïssé, F. Joly

Annals of Oncology. 2007;18(6):1064-1070

Link1 Link2 Link3

Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?

Avishay Sella

Nature Clinical Practice Urology. 2005;2(1):18-19

Link1 Link2

Link3

Dose-Finding Study of Weekly Docetaxel plus Estramustine in Patients with Hormone-Refractory Metastatic Prostate Cancer

Mariarosa Coccaro, Alfredo Tartarone, Gianpiero Romano, Raffaele Ardito, Nicola Di Renzo

Tumori Journal. 2005;91(4):314-316

Link1 Link2

Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?

Cora N Sternberg

Nature Clinical Practice Urology. 2005;2(1):20-21

Link1 Link2

Link3

Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?

Andrew Protheroe

Nature Clinical Practice Oncology. 2005;2(2):68-69

Link1

Link2 Link3 Link4

Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?

Stefan Sleijfer, Gerrit Stoter

Nature Clinical Practice Oncology. 2005;2(2):70-71

Link1

Link2 Link3 Link4

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

W BERRY

Seminars in Oncology. 2001;28:8-15

Link1 Link2

Docetaxel plus Prednisone versus Mitoxantrone plus Prednisone for Metastatic Hormone-Refractory Prostate Cancer in Chinese Patients: Experience of a Single Center

Hai Liang Zhang, Ding Wei Ye, Xu Dong Yao, Bo Dai, Shi Lin Zhang, Yi Jun Shen, Yao Zhu, Wen Zhang

Urologia Internationalis. 2007;79(4):307-311

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.